Arteris CEO sells 11,145 shares in Form 4

Rhea-AI Filing Summary

Arteris, Inc. insider trading report: President and CEO Charles Janac, who is also a director and 10% owner of Arteris, reported selling 11,145 shares of common stock on 01/06/2026 at a weighted average price of $16.9032 per share, in transactions executed between $15.86 and $17.65. The sale was made under a Rule 10b5-1 trading plan adopted on March 5, 2025.

After this sale, Janac directly beneficially owned 139,487 Arteris shares. He also had indirect beneficial ownership of 9,469,071 shares held by Bayview Legacy, LLC, where he is the manager and has voting and dispositive power, and 56,252 shares held by the Charles and Lydia Janac Trust, for which he serves as trustee.

Insider Trade Summary

Net Seller: 11,145 shares

Net Sell 3 txns

Insider JANAC K CHARLES

Role President and CEO

Sold 11,145 shs ($188K)

Type	Security	Shares	Price	Value
Sale	Common Stock	11,145	$16.9032	$188K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 139,487 shares (Direct); Common Stock — 9,469,071 shares (Indirect, Bayview Legacy, LLC); Common Stock — 56,252 shares (Indirect, Charles and Lydia Janac Trust)

Footnotes (4)

1. F1. Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on March 5, 2025.
2. F2. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.86 to $17.65 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The Reporting Person is the manager of Bayview Legacy, LLC and as such is deemed to have voting and dispositive power of the shares beneficially owned by Bayview Legacy, LLC.
4. F4. The shares are held by Charles and Lydia Janac Trust, for which the Reporting Person serves as trustee.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Arteris (AIP) shares did CEO Charles Janac sell in this Form 4?

The Form 4 reports that President and CEO Charles Janac sold 11,145 shares of Arteris common stock on 01/06/2026.

What was the sale price for the Arteris (AIP) shares sold by the CEO?

The shares were sold at a weighted average price of $16.9032 per share, in multiple trades at prices ranging from $15.86 to $17.65.

Was the Arteris (AIP) CEO sale part of a Rule 10b5-1 trading plan?

Yes. The sale was made pursuant to a Rule 10b5-1 trading plan that was adopted on March 5, 2025 by the reporting person.

How many Arteris (AIP) shares does Charles Janac own directly after this transaction?

Following the reported sale, Charles Janac directly beneficially owned 139,487 shares of Arteris common stock.

What indirect Arteris (AIP) holdings are reported for Charles Janac?

The filing shows 9,469,071 shares indirectly held through Bayview Legacy, LLC, where he is manager with voting and dispositive power, and 56,252 shares held by the Charles and Lydia Janac Trust, where he serves as trustee.

What roles does Charles Janac hold at Arteris (AIP) according to this filing?

The reporting person is identified as a Director, President and CEO, and a 10% owner of Arteris, Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/08/2026 - 04:29 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JANAC K CHARLES

(Last) (First) (Middle)

C/O ARTERIS, INC.

900 E. HAMILTON AVE., SUITE 300

(Street)

CAMPBELL CA 95008

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arteris, Inc. [ AIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		S(1)		11,145	D	$16.9032(2)	139,487	D
Common Stock								9,469,071	I	Bayview Legacy, LLC(3)
Common Stock								56,252	I	Charles and Lydia Janac Trust(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on March 5, 2025.

2. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.86 to $17.65 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The Reporting Person is the manager of Bayview Legacy, LLC and as such is deemed to have voting and dispositive power of the shares beneficially owned by Bayview Legacy, LLC.

4. The shares are held by Charles and Lydia Janac Trust, for which the Reporting Person serves as trustee.

Remarks:

	/s/ Paul Alpern, as Attorney-in-Fact for JANAC K CHARLES	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.